Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -40.52% | -404.41% | -147.73% | 36.33% | -1.85% |
| Total Depreciation and Amortization | 120.68% | -3.31% | 7.09% | -35.68% | 88.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -687.88% | -65.43% | 80.26% | 219.17% | -205.52% |
| Change in Net Operating Assets | -52.99% | 196.88% | -300.37% | 72.20% | -55.39% |
| Cash from Operations | -626.04% | 156.53% | -220.30% | 162.56% | -5,693.80% |
| Capital Expenditure | -47.19% | -23.61% | 78.44% | -99.40% | -174.59% |
| Sale of Property, Plant, and Equipment | 16.67% | -45.45% | -- | -100.00% | 1,700.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 447.28% | -245.53% | 442.14% | -134.65% | -19.97% |
| Cash from Investing | 419.38% | -265.31% | 248.20% | -192.10% | -31.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 852.38% | -93.40% | 536.00% | -99.79% | 1,540.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | 108.32% | -3,029.75% |
| Cash from Financing | -138.10% | -93.40% | -12.88% | -98.20% | 1,406.32% |
| Foreign Exchange rate Adjustments | 125.61% | 124.41% | 8.55% | 392.50% | -180.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,570.07% | 112.94% | -185.20% | -72.23% | 335.80% |